Table 1.
Baseline demographics and characteristics
| All n (%) |
Group with EF ≥35% n (%) |
Group with EF <35% n (%) |
|
|---|---|---|---|
| Number of patients | 143 | 28 | 114 |
| Gender | 109 (76%) Male 34 (24%) Female |
22 (79%) Male 6 (21%) Female |
87 (76%) Male 27 (24%) Female |
| Age [completed life years] | 62 ± 12 | 65 ± 12 | 63 ± 12 |
| Subjects with ICD | 108 (76%) | 16 (57%)* | 91 (80%) |
| Etiology of cardiomyopathy | 69 (50%)—Ischemic 57 (41%)—Idiopathic 13 (9%)—other |
N = 27 16 (59%)—Ischemic 8 (30%)—Idiopathic 3 (11%)—other |
N = 111 52 (47%)—Ischemic 49 (44%)—Idiopathic 10 (9%)—other |
| History of CABG and/or PCI | 76 (57%) | N = 14 (50%) | N = 61 (56%) |
| QRS duration (ms) | 118 ± 26 (N = 131) |
N = 24 112 ± 17* |
N = 106 119 ± 27 |
| NYHA class [Class—N (%)] |
II—29 (20%) III—103 (72%) IV—11 (8%) |
II—7 (25%) III—21 (75%) IV—0 (0%) |
II—22 (19%) III—81 (71%) IV—11 (10%) |
| Hypertension—N (%) | 66 (49%) |
N = 108 14 (54%) |
N = 108 51 (47%) |
| Presence of CRT—N (%) | 14 (10%) | 2 (7%) | 12 (11%) |
| Cardiac medications | N = 133 | N = 26 | N = 107 |
| Diuretic | 104 (78%) | 19 (73%) | 85 (79%) |
| ACE-I | 82 (62%) | 17 (65%) | 65 (61%) |
| ARB | 32 (24%) | 8 (31%) | 24 (22%) |
| B-Blocker | 126 (95%) | 24 (92%) | 102 (95%) |
| Aldosterone inhibitor | 87 (65%) | 18 (69%) | 69 (64%) |
| Digoxin | 19 (14%) | 4 (15%) | 15 (14%) |
| Other medications | |||
| Anticoagulation | 49 (37%) | 8 (31%) | 41 (38%) |
| Antiplatelet Therapy | 78 (59%) | 20 (77%) | 58 (54%) |
| Statin | 92 (69%) | 21 (81%) | 71 (66%) |
For one subject the baseline EF was not known, hence while the entire cohort is of 143 subjects, the total number of subjects in both groups (based on baseline EF) combined, is only 142. * p < 0.05 vs. Group with EF< 35%